New York, NY – A recent study suggests that a drug typically used to treat obesity may have the potential to prevent Covid deaths. The drug in question, Wegovy, has shown promising results in reducing the chances of severe outcomes in Covid-19 patients, particularly those with obesity.
The findings, which come from a pooled analysis of various studies, point to the potential benefits of using Wegovy as a preventative measure for Covid-19. Researchers have found that not only does Wegovy reduce the risk of severe illness in Covid patients with obesity, but it also decreases their chances of mortality from the virus.
This development is significant, as obesity has been identified as a risk factor for severe Covid-19 outcomes. By utilizing a drug like Wegovy, individuals with obesity may have a better chance of fighting off the virus and avoiding serious complications.
Furthermore, the study also highlights the potential of another obesity drug, Ozempic, in reducing the risk of severe Covid-19 outcomes. With both Wegovy and Ozempic showing promise in combating the virus, there is hope for better outcomes for individuals with obesity who contract Covid-19.
Overall, these findings shed light on the potential of repurposing existing drugs to fight against the ongoing Covid-19 pandemic. As researchers continue to explore different treatment options, drugs like Wegovy and Ozempic provide a glimmer of hope for those most at risk of severe outcomes from the virus.